BACKGROUND: For more than three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has provided a framework to quantify health loss due to diseases, injuries, and associated risk factors. This paper presents GBD 2023 findings on disease and injury burden and risk-attributable health loss, offering a global audit of the state of world health to inform public health priorities. This work captures the evolving landscape of health metrics across age groups, sexes, and locations, while reflecting on the remaining post-COVID-19 challenges to achieving our collective global health ambitions. METHODS: The GBD 2023 combined analysis estimated years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 375 diseases and injuries, and risk-attributable burden associated with 88 modifiable risk factors. Of the more than 310 000 total data sources used for all GBD 2023 (about 30% of which were new to this estimation round), more than 120 000 sources were used for estimation of disease and injury burden and 59 000 for risk factor estimation, and included vital registration systems, surveys, disease registries, and published scientific literature. Data were analysed using previously established modelling approaches, such as disease modelling meta-regression version 2.1 (DisMod-MR 2.1) and comparative risk assessment methods. Diseases and injuries were categorised into four levels on the basis of the established GBD cause hierarchy, as were risk factors using the GBD risk hierarchy. Estimates stratified by age, sex, location, and year from 1990 to 2023 were focused on disease-specific time trends over the 2010-23 period and presented as counts (to three significant figures) and age-standardised rates per 100 000 person-years (to one decimal place). For each measure, 95% uncertainty intervals [UIs] were calculated with the 2·5th and 97·5th percentile ordered values from a 250-draw distribution. FINDINGS: Total numbers of global DALYs grew 6·1% (95% UI 4·0-8·1), from 2·64 billion (2·46-2·86) in 2010 to 2·80 billion (2·57-3·08) in 2023, but age-standardised DALY rates, which account for population growth and ageing, decreased by 12·6% (11·0-14·1), revealing large long-term health improvements. Non-communicable diseases (NCDs) contributed 1·45 billion (1·31-1·61) global DALYs in 2010, increasing to 1·80 billion (1·63-2·03) in 2023, alongside a concurrent 4·1% (1·9-6·3) reduction in age-standardised rates. Based on DALY counts, the leading level 3 NCDs in 2023 were ischaemic heart disease (193 million [176-209] DALYs), stroke (157 million [141-172]), and diabetes (90·2 million [75·2-107]), with the largest increases in age-standardised rates since 2010 occurring for anxiety disorders (62·8% [34·0-107·5]), depressive disorders (26·3% [11·6-42·9]), and diabetes (14·9% [7·5-25·6]). Remarkable health gains were made for communicable, maternal, neonatal, and nutritional (CMNN) diseases, with DALYs falling from 874 million (837-917) in 2010 to 681 million (642-736) in 2023, and a 25·8% (22·6-28·7) reduction in age-standardised DALY rates. During the COVID-19 pandemic, DALYs due to CMNN diseases rose but returned to pre-pandemic levels by 2023. From 2010 to 2023, decreases in age-standardised rates for CMNN diseases were led by rate decreases of 49·1% (32·7-61·0) for diarrhoeal diseases, 42·9% (38·0-48·0) for HIV/AIDS, and 42·2% (23·6-56·6) for tuberculosis. Neonatal disorders and lower respiratory infections remained the leading level 3 CMNN causes globally in 2023, although both showed notable rate decreases from 2010, declining by 16·5% (10·6-22·0) and 24·8% (7·4-36·7), respectively. Injury-related age-standardised DALY rates decreased by 15·6% (10·7-19·8) over the same period. Differences in burden due to NCDs, CMNN diseases, and injuries persisted across age, sex, time, and location. Based on our risk analysis, nearly 50% (1·27 billion [1·18-1·38]) of the roughly 2·80 billion total global DALYs in 2023 were attributable to the 88 risk factors analysed in GBD. Globally, the five level 3 risk factors contributing the highest proportion of risk-attributable DALYs were high systolic blood pressure (SBP), particulate matter pollution, high fasting plasma glucose (FPG), smoking, and low birthweight and short gestation-with high SBP accounting for 8·4% (6·9-10·0) of total DALYs. Of the three overarching level 1 GBD risk factor categories-behavioural, metabolic, and environmental and occupational-risk-attributable DALYs rose between 2010 and 2023 only for metabolic risks, increasing by 30·7% (24·8-37·3); however, age-standardised DALY rates attributable to metabolic risks decreased by 6·7% (2·0-11·0) over the same period. For all but three of the 25 leading level 3 risk factors, age-standardised rates dropped between 2010 and 2023-eg, declining by 54·4% (38·7-65·3) for unsafe sanitation, 50·5% (33·3-63·1) for unsafe water source, and 45·2% (25·6-72·0) for no access to handwashing facility, and by 44·9% (37·3-53·5) for child growth failure. The three leading level 3 risk factors for which age-standardised attributable DALY rates rose were high BMI (10·5% [0·1 to 20·9]), drug use (8·4% [2·6 to 15·3]), and high FPG (6·2% [-2·7 to 15·6]; non-significant). INTERPRETATION: Our findings underscore the complex and dynamic nature of global health challenges. Since 2010, there have been large decreases in burden due to CMNN diseases and many environmental and behavioural risk factors, juxtaposed with sizeable increases in DALYs attributable to metabolic risk factors and NCDs in growing and ageing populations. This long-observed consequence of the global epidemiological transition was only temporarily interrupted by the COVID-19 pandemic. The substantially decreasing CMNN disease burden, despite the 2008 global financial crisis and pandemic-related disruptions, is one of the greatest collective public health successes known. However, these achievements are at risk of being reversed due to major cuts to development assistance for health globally, the effects of which will hit low-income countries with high burden the hardest. Without sustained investment in evidence-based interventions and policies, progress could stall or reverse, leading to widespread human costs and geopolitical instability. Moreover, the rising NCD burden necessitates intensified efforts to mitigate exposure to leading risk factors-eg, air pollution, smoking, and metabolic risks, such as high SBP, BMI, and FPG-including policies that promote food security, healthier diets, physical activity, and equitable and expanded access to potential treatments, such as GLP-1 receptor agonists. Decisive, coordinated action is needed to address long-standing yet growing health challenges, including depressive and anxiety disorders. Yet this can be only part of the solution. Our response to the NCD syndemic-the complex interaction of multiple health risks, social determinants, and systemic challenges-will define the future landscape of global health. To ensure human wellbeing, economic stability, and social equity, global action to sustain and advance health gains must prioritise reducing disparities by addressing socioeconomic and demographic determinants, ensuring equitable health-care access, tackling malnutrition, strengthening health systems, and improving vaccination coverage. We live in times of great opportunity. FUNDING: Gates Foundation and Bloomberg Philanthropies.

Zobrazit více v PubMed

Murray CJL. The Global Burden of Disease Study at 30 years. Nat Med. 2022;28:2019–2026. PubMed

WHO World health statistics 2025: monitoring health for the SDGs, Sustainable Development Goals. 2025. https://iris.who.int/bitstream/handle/10665/381418/9789240110496-eng.pdf

Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–2223. PubMed

GBD 2015 DALYs and HALE Collaborators Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1603–1658. PubMed PMC

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858. PubMed PMC

GBD 2019 Diseases and Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222. PubMed PMC

GBD 2021 Diseases and Injuries Collaborators Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2133–2161. PubMed PMC

Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–2260. PubMed PMC

GBD 2015 Risk Factors Collaborators Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1659–1724. PubMed PMC

GBD 2016 Risk Factors Collaborators Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1345–1422. PubMed PMC

GBD 2017 Risk Factor Collaborators Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1923–1994. PubMed PMC

GBD 2019 Risk Factors Collaborators Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223–1249. PubMed PMC

GBD 2021 Risk Factors Collaborators Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2162–2203. PubMed PMC

Zheng P, Afshin A, Biryukov S, et al. The Burden of Proof studies: assessing the evidence of risk. Nat Med. 2022;28:2038–2044. PubMed PMC

Zheng P, Barber R, Sorensen RJD, Murray CJL, Aravkin AY. Trimmed constrained mixed effects models: formulations and algorithms. J Comput Graph Stat. 2021;30:544–556.

GBD 2023 Causes of Death Collaborators Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025 doi: 10.1016/S0140-6736(25)01917-8. published online Oct 12. PubMed DOI

Institute for Health Metrics and Evaluation Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) Protocol. 2024. https://www.healthdata.org/sites/default/files/2024-06/GBD%20Protocol%20060424.pdf published online June 4.

Sullivan DF. A single index of mortality and morbidity. HSMHA Health Rep. 1971;86:347–354. PubMed PMC

Murray CJ, Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S. Comparative quantification of health risks conceptual framework and methodological issues. Popul Health Metr. 2003;1:1. PubMed PMC

Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349:1436–1442. PubMed

Dai X, Gil GF, Reitsma MB, et al. Health effects associated with smoking: a Burden of Proof study. Nat Med. 2022;28:2045–2055. PubMed PMC

Lescinsky H, Afshin A, Ashbaugh C, et al. Health effects associated with consumption of unprocessed red meat: a Burden of Proof study. Nat Med. 2022;28:2075–2082. PubMed PMC

Razo C, Welgan CA, Johnson CO, et al. Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study. Nat Med. 2022;28:2056–2065. PubMed PMC

Stanaway JD, Afshin A, Ashbaugh C, et al. Health effects associated with vegetable consumption: a Burden of Proof study. Nat Med. 2022;28:2066–2074. PubMed PMC

Flor LS, Anderson JA, Ahmad N, et al. Health effects associated with exposure to secondhand smoke: a Burden of Proof study. Nat Med. 2024;30:149–167. PubMed PMC

Spencer CN, Khalil M, Herbert M, et al. Health effects associated with exposure to intimate partner violence against women and childhood sexual abuse: a burden of proof study. Nat Med. 2023;29:3243–3258. PubMed PMC

Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet. 2016;388:e19–e23. PubMed

GBD 2021 Demographics Collaborators Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:1989–2056. PubMed PMC

GBD 2023 Demographics Collaborators Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023. Lancet. 2025 doi: 10.1016/S0140-6736(25)01330-3. published online Oct 12. PubMed DOI

Apeagyei AE, Bisignano C, Elliott H, et al. Tracking development assistance for health, 1990–2030: historical trends, recent cuts, and outlook. Lancet. 2025;406:337–348. PubMed PMC

Institute for Health Metrics and Evaluation (IHME) IHME; Seattle, WA: 2025. Financing Global Health 2025: cuts in aid and future outlook.

GBD 2021 US Obesity Forecasting Collaborators National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050. Lancet. 2024;404:2278–2298. PubMed PMC

GBD 2021 Adult BMI Collaborators Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study. Lancet. 2021;405:813–838. PubMed PMC

GBD 2021 Adolescent BMI Collaborators Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405:785–812. PubMed PMC

Ong KL, Stafford LK, McLaughlin SA, et al. the GBD 2021 Diabetes Collaborators Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402:203–234. PubMed PMC

GBD 2023 Kidney Failure with Replacement Therapy Collaborators Global, regional, and national prevalence of kidney failure with replacement therapy and associated aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Glob Health. 2025;13:e1378–e1395. PubMed

Zaman S, Wasfy JH, Kapil V, et al. The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma. Lancet. 2025;405:1264–1312. PubMed PMC

Marcus ME, Manne-Goehler J, Theilmann M, et al. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Glob Health. 2022;10:e369–e379. PubMed PMC

Roser P, Bajaj SS, Stanford FC. International lack of equity in modern obesity therapy: the critical need for change in health policy. Int J Obes. 2022;46:1571–1572. PubMed PMC

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–2232. PubMed

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–216. PubMed

WHO MPOWER. https://www.who.int/initiatives/mpower

Murphy T. Pliny the Elder's Natural History: the empire in the encyclopedia. March 11, 2004. DOI

McConnell JR, Chellman NJ, Plach A, et al. Pan-European atmospheric lead pollution, enhanced blood lead levels, and cognitive decline from Roman-era mining and smelting. Proc Natl Acad Sci USA. 2025;122 PubMed PMC

Huang X, Steinmetz J, Marsh EK, et al. A systematic review with a Burden of Proof meta-analysis of health effects of long-term ambient fine particulate matter (PM2·5) exposure on dementia. Nat Aging. 2025;5:897–908. PubMed PMC

GBD 2019 Diabetes and Air Pollution Collaborators Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2·5 air pollution, 1990–2019: an analysis of data from the Global Burden of Disease Study 2019. Lancet Planet Health. 2022;6:e586–e600. PubMed PMC

Semmens EO, Leary CS, Fitzpatrick AL, et al. Air pollution and dementia in older adults in the Ginkgo Evaluation of Memory Study. Alzheimers Dement. 2023;19:549–559. PubMed PMC

GBD 2021 HAP Collaborators Global, regional, and national burden of household air pollution, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2025;405:1167–1181. PubMed PMC

WHO Seventy-eighth World Health Assembly—daily update. 26 May 2025. https://www.who.int/news/item/26-05-2025-seventy-eighth-world-health-assembly—daily-update–26-may-2025

Blake JA, Sourander A, Kato A, Scott JG. Will restricting the age of access to social media reduce mental illness in Australian youth? Aust N Z J Psychiatry. 2025;59:202–208. PubMed PMC

Santomauro DF, Mantilla Herrera AM, Shadid J, et al. the COVID-19 Mental Disorders Collaborators Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398:1700–1712. PubMed PMC

Haidt J. Penguin Press; 2024. The anxious generation: how the great rewiring of childhood is causing an epidemic of mental illness.

Fassi L, Thomas K, Parry DA, Leyland-Craggs A, Ford TJ, Orben A. Social media use and internalizing symptoms in clinical and community adolescent samples: a systematic review and meta-analysis. JAMA Pediatr. 2024;178:814–822. PubMed PMC

Women UN Facts and figures: ending violence against women. Nov 25, 2024. https://www.unwomen.org/en/articles/facts-and-figures/facts-and-figures-ending-violence-against-women

Sardinha L, Maheu-Giroux M, Stöckl H, Meyer SR, García-Moreno C. Global, regional, and national prevalence estimates of physical or sexual, or both, intimate partner violence against women in 2018. Lancet. 2022;399:803–813. PubMed PMC

The Lancet The demise of USAID: time to rethink foreign aid? Lancet. 2025;405:951. PubMed

Wu Y, Wulf Hanson S, Culbreth G, et al. Assessing the impact of health-care access on the severity of low back pain by country: a case study within the GBD framework. Lancet Rheumatol. 2024;6:e598–e606. PubMed PMC

Santomauro DF, Purcell C, Whiteford HA, Ferrari AJ, Vos T. Grading disorder severity and averted burden by access to treatment within the GBD framework: a case study with anxiety disorders. Lancet Psychiatry. 2023;10:272–281. PubMed PMC

Yap Y-S, Lu Y-S, Tamura K, et al. Insights into breast cancer in the East vs the West: a review. JAMA Oncol. 2019;5:1489–1496. PubMed

GBD 2019 Healthcare Access and Quality Collaborators Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Glob Health. 2022;10:e1715–e1743. PubMed PMC

Disease burden attributable to intimate partner violence against females and sexual violence against children in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

Quantifying the fatal and non-fatal burden of disease associated with child growth failure, 2000-2023: a systematic analysis from the Global Burden of Disease Study 2023

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023